Braveheart Bio

Clinical-stage biopharma developing an oral cardiac myosin inhibitor for people with hypertrophic cardiomyopathy

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-11-14

Recent signals

What changed at Braveheart Bio in the last 6 months, newest first. Each line links to its public source.

  • 6 Nov 2026 Leadership hire · Hiring Director/Senior Director, Clinical Quality (San Francisco) job-boards.greenhouse.io
  • 21 Oct 2026 Leadership hire · Hiring Associate Director/Director, Medical Affairs (San Francisco) job-boards.greenhouse.io
  • 20 Oct 2026 Leadership hire · Hiring (Senior) Director, Regulatory Affairs CMC (San Francisco) job-boards.greenhouse.io

Get signals like these for the companies you sell to →

About Braveheart Bio

Braveheart Bio develops BHB-1893, an oral cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM) and related conditions. The drug is in two global Phase 3 programs: LIONHEART-HCM in obstructive HCM and NOBLEHEART-HCM in non-obstructive HCM. More than 300 clinical study participants have been dosed with BHB-1893 to date.

The company holds exclusive rights to develop and commercialize BHB-1893 worldwide outside Greater China, under a license from Jiangsu Hengrui Pharmaceuticals, which discovered the molecule and continues its development in Greater China. The target patients are people with obstructive and non-obstructive HCM, a population the company estimates at more than 700,000 in the U.S.

Braveheart Bio launched in 2025 and is listed on the Nasdaq Global Market under the ticker BRVE. Its leadership team includes Chief Executive Officer Travis Murdoch, M.D. Open roles span regulatory affairs, clinical quality, clinical science, clinical operations, medical affairs and finance, listed for San Francisco, CA, remote or hybrid.

Product: BHB-1893, an oral cardiac myosin inhibitor in global Phase 3 development for obstructive and non-obstructive hypertrophic cardiomyopathy.

Jobs at Braveheart Bio

No open positions in Europe right now.

Open roles at Braveheart Bio in the Americas (3)

United States 3. From Braveheart Bio's careers page or applicant tracking system; each role links to the employer.

More biotech & pharma companies

  • BridgeBio Pharma

    Develops drugs for rare genetic conditions, including ATTR amyloidosis, achondroplasia and muscular dystrophy
    United StatesBiotech & pharma16 open jobs
    GrowingRemote-friendly
  • Bristolmyerssquibb

    Discovers, develops and supplies medicines for patients with serious diseases worldwide
    New York, United StatesBiotech & pharma116 open jobs
  • Calico

    Biology research and drug development targeting aging and age-related diseases for patients and clinical partners
    United StatesBiotech & pharma
    New on Evolc
  • cAMPfield Therapeutics

    Clinical-stage biopharma developing prifemilast, an oral PDE4B inhibitor, for ulcerative colitis and Crohn's disease
    San Diego, United StatesBiotech & pharmaFounded 2026
    Young companyNew on Evolc
  • Capable Labs

    AI-driven therapeutics developer building peptide and RNA drugs, starting with sleep disorder programs
    United StatesBiotech & pharma
    New on Evolc
  • Celcuity

    Develops targeted cancer therapies for patients with cancers involving the PAM pathway
    United StatesBiotech & pharma
    New on Evolc

All biotech & pharma companies →

Website technologies

Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.

Analytics

  • Google Tag ManagerMedium confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Content delivery

Content management

  • WebflowHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Hosting

  • AWSHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.